
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Mayo Clinic
Deal Size : Undisclosed
Deal Type : Collaboration
SpineThera Collaborates with Mayo Clinic for Substance Abuse Disorder Solutions
Details : The collaboration aims to develop long-acting injectable drugs to improve treatment outcomes for individuals with substance abuse disorders using it’s novel, long-acting injectable technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Mayo Clinic
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SX600 (dexamethasone) is a novel formulation of extended-release microspheres designed for transforaminal epidural injection in the management of sciatica pain.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexamethasone
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SX600, is novel formulation of dexamethasone acetate microspheres for micro-suspension injection, was designed as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved profile relative to radicular leg pai...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Department of Defense
Deal Size : $5.0 million
Deal Type : Funding
SpineThera Awarded $5 Million Grant from Department of Defense
Details : The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process development and scale-up activities. Together, these activities will position SX600 for future Phase 3 clinical trials.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
April 26, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Department of Defense
Deal Size : $5.0 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SX600
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SX600 is a Steroid drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Radiculopathy.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
May 16, 2019
Lead Product(s) : SX600
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
